Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Otsuka

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Otsuka's 2012 sales performance.

Otsuka

Cortellis Drugs to Watch in 2020 report

Cortellis Drugs to Watch in 2020 report

4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD).

Digital divergence

Digital divergence Failed relationships. What we’ve seen recently – for example when Otsuka and Proteus ended their collaboration – is a number of pharma companies looking at digital partners, seeing value in getting together,

Teva’s weak pipeline hit by Tourette’s drug trial failure

Teva’s weak pipeline hit by Tourette’s drug trial failure 110 and Otsuka’s well-established antipsychotic drug Abilify (aripiprazole), which is in a trial with data due next year.

Merck strengthens KRAS stake with Taiho and Astex partnership

Merck strengthens KRAS stake with Taiho and Astex partnership Partner companies could gain $2.5bn in milestone payments. Merck &Co/MSD has announced a partnership with Otsuka's Taiho unit and Cambridge, UK-based biotech Astex Pharmaceuticals for the development ... Otsuka’s Taiho has retained co-commercialisation

Low-dose LSD looks safe for Alzheimer’s patients, but will it work?

Low-dose LSD looks safe for Alzheimer’s patients, but will it work? Other treatments targeting serotonin pathways in Alzheimer’s haven’t proved to be successful – such as Lundbeck and Otsuka’s 5-HT.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...